Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2000
11/29/2000CN1275162A Death domain containing receptor 5
11/29/2000CN1274723A Dicyclic compound, medicine composition containing the same and use thereof
11/29/2000CN1274719A Process for preparation of substituted pyridine compound
11/29/2000CN1274601A Immunity-strengthening and infection-preventing medicine
11/29/2000CN1058964C Branched-amino-sbustituted thiazoles, process for their preparation and the pharmaceutical compositions which contain them
11/28/2000US6153655 Terminally-branched polymeric linkers and polymeric conjugates containing the same
11/28/2000US6153653 Choline compositions and uses thereof
11/28/2000US6153651 Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
11/28/2000US6153628 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as αv β3 antagonists
11/28/2000US6153625 For treatment of disorders in which involvement of serotoninergic system has been demonstrated, as in psychiartic disorders such as depression, anxiety, panic attack, schizophrenia, aggression, impulsive disorders
11/28/2000US6153624 Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
11/28/2000US6153622 Estrogen agonists/antagonists
11/28/2000US6153615 Administering nitric oxide synthesis inhibiting amount of dihydrofolate reductase inhibitor, catecholamine replacing non-toxic amount of levodopa with or without carbidopa and serotonin replacing non-toxic amount of l-5-hydroxytryptophane
11/28/2000US6153614 Piperazinyl pyrimidine dione compounds selective for adrenoceptors
11/28/2000US6153611 As non-dopaminergic antiischemic compounds for treating brain disorders
11/28/2000US6153604 Treating disease of nervous system in which pathophysiology of disorder involves excessive excitation of nerve cells by agonists of nmda receptors, comprising administering to guanidine derivative
11/28/2000US6153588 Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-β-cyclohexyl alanine amide
11/28/2000US6153220 Taste-masked formulations
11/28/2000US6153217 Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
11/28/2000US6153189 Human TRK receptors and neurotrophic factor inhibitors
11/28/2000CA2309505A1 New 4-arylpiperidine derivatives for the treatment of pruritus
11/28/2000CA2200795C Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
11/28/2000CA2172149C Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
11/28/2000CA2127199C Prevention and treatment of ischemic events and reperfusion injury resulting therefrom
11/28/2000CA2085037C Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
11/23/2000WO2000070076A1 Tm4sf receptors
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070045A1 Ox2 receptor homologs
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000069908A1 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto
11/23/2000WO2000069884A2 Compositions isolated from skin cells and methods for their use
11/23/2000WO2000069861A1 THIAZOLOPYRIMIDINES USEFUL AS TNFα INHIBITORS
11/23/2000WO2000069860A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000WO2000069855A2 Furanone derivatives as inhibitors of cathepsin s
11/23/2000WO2000069848A1 Compounds having cytokine inhibitory activity
11/23/2000WO2000069847A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000WO2000069846A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069833A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000WO2000069832A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000WO2000069831A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
11/23/2000WO2000069826A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069820A1 Cyclic amine derivatives and their uses
11/23/2000WO2000069819A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000WO2000069474A1 Methods for treating avm' using radioactive compositions
11/23/2000WO2000069469A1 Topical compositions for prostaglandin e1 delivery
11/23/2000WO2000069446A1 Combination therapy for treating hypercholesterolemia
11/23/2000WO2000069445A1 Combination therapy for treating hypercholesterolemia
11/23/2000WO2000069412A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
11/23/2000WO2000069257A2 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000043354A3 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000040232A3 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000034295A3 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000032267A3 Device for locally delivering a drug in a body cavity
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000031100A3 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000030627A3 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
11/23/2000WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
11/23/2000WO2000026348A3 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO1999048482A3 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
11/23/2000DE19923086A1 New cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, are ATP-sensitive potassium channel inhibitors and vagal nervous system stimulants useful for treating cardiovascular disorders
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000DE19918446A1 Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen Use of coxsackievirus B3 to improve the transfection of cells
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374297A1 Furanone derivatives as inhibitors of cathepsin s
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373610A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000CA2373607A1 Cyclic amine derivatives and their uses
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372494A1 Compounds having cytokine inhibitory activity
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372051A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000CA2370066A1 Thiazolopyrimidines useful as tnf.alpha. inhibitors
11/23/2000CA2369983A1 Methods for treating avm's using radioactive compositions
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053245A1 45 human secreted proteins
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053224A1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
1 ... 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 ... 1595